AACR Annual Meeting

Potential New Approach to Melanoma

Phoebe Starr

May 2014, Vol 5, No 4 - AACR Annual Meeting

San Diego, CA—Preliminary results suggest that an investigational antibody-drug conjugate called DEDN-6526A (Seattle Genetics, Genentech) has activity against melanoma, including cutaneous, mucosal, and ocular melanoma, which is considered difficult to treat. The new drug comes on the heels of trastuzumab emtansine, the first antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of breast cancer. [ Read More ]

AG-221 Achieved Excellent Responses in Relapsed, Refractory Leukemia, Myelodysplastic Syndrome

Phoebe Starr

May 2014, Vol 5, No 4 - AACR Annual Meeting

San Diego, CA—Preliminary data suggest that a novel agent called AG-221 can induce complete remissions (CRs) in patients with relapsed, refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who harbor mutated IDH2. These exciting results were achieved in patients with an ominous prognosis who have few or no other treatment options. The data were presented at the 2014 American Association for Cancer Research (AACR) annual meeting. [ Read More ]

Genetically Engineered T Cells for Childhood Leukemia

May 2013, Vol 4, No 4 - AACR Annual Meeting

Washington, DC—Although still in very early-phase testing in humans, the results of 2 small studies in children suggest that reinfusing autologous genetically engineered T cells can reverse acute lymphocytic leukemia (ALL) in children. Both studies were presented at the 2013 American Association for Cancer Research meeting.

All the children had run out of treatment options and were close to death; 2 had a remarkable recovery after T-cell therapy and remain in complete remission.

[ Read More ]